ABSTRACT:
Background: Aside from being the main goal for therapy, Health-Related Quality of Life (HRQOL) also can also be used for pharmacoeconomic analysis or Health Technology Assessment (HTA). The Study on HRQOL employing the EQ-5D-5L questionnaire was still limited. It aims to calculate the HRQOL according to health status and to know the determinant factors which affect the NSCLC mutation EGFR patients' quality of life. Methods and Material: A cross-sectional study was performed by interviewing with the patients using EQ 5D 5L questionnaire in RSUP Dr. Sardjito, Yogyakarta and RSUP Dr. Kariadi, Semarang, Indonesia Patients’ health status was consisted of Progression Free / PF (no progression), Progressive Disease 1 / PD1 (experiencing progression before or when diagnosed NSCLC with mutation of EGFR), and Progressive Disease2/PD2 (experiencing progression after being diagnosed NCLC with mutation of EGFR) Result: There were 74 patients identified, 29 patients had not experienced disease progression (PF), 21 patients experienced the progress before or altogether after being diagnosed with NSCLC EGFR mutation positive (PD1), and 24 patients experienced the progression of the disease after being diagnosed with NSCLC EGFR mutation positive (PD2). Common problems occurred such as pain and usual activities (75,7% and 60,8%.). The mean of the utility value (SD) on patients PF, PD1, and PD2 were 0,824 (0,164); 0,528 (0,489); 0,544 (0,339). The mean of EQ5D VAS on PF, PD1, and PD2 patients were 69,65 (9,904); 57,14 (16,09); 53,95 (11,12). Mann Whitney test and Kruskal-Wallis test showed that age, gender, and mutation type did not affect the patients' utility, yet according to descriptive statistic and Kruskal-Wallis test, it was shown that health status affects patients' HRQOL. Conclusion: NSCL EGFR mutation brought negative impact on patients' HRQOL and patients' health status significantly affected HRQOL in NSCLC EGFR mutation-positive patients.